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The biological function of inhibin-a subunit (INHa) in prostate cancer (PCa) is currently unclear. A recent study associated elevated
levels of INHa in PCa patients with a higher risk of recurrence. This prompted us to use clinical specimens and functional studies to
investigate the pro-tumourigenic and pro-metastatic function of INHa. We conducted a cross-sectional study to determine a link
between INHa expression and a number of clinicopathological parameters including Gleason score, surgical margin, extracapsular
spread, lymph node status and vascular endothelial growth factor receptor-3 expression, which are well-established prognostic
factors of PCa. In addition, using two human PCa cell lines (LNCaP and PC3) representing androgen-dependent and -independent
PCa respectively, we investigated the biological function of elevated levels of INHa in advanced cancer. Elevated expression of INHa
in primary PCa tissues showed a higher risk of PCa patients being positive for clinicopathological parameters outlined above. Over-
expressing INHa in LNCaP and PC3 cells demonstrated two different and cell-type-specific responses. INHa-positive LNCaP
demonstrated reduced tumour growth whereas INHa-positive PC3 cells demonstrated increased tumour growth and metastasis
through the process of lymphangiogenesis. This study is the first to demonstrate a pro-tumourigenic and pro-metastatic function for
INHa associated with androgen-independent stage of metastatic prostate disease. Our results also suggest that INHa expression in
the primary prostate tumour can be used as a predictive factor for prognosis of PCa.
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Inhibins A and B are members of the transforming growth factor-b
(TGFb) superfamily. Inhibins are heterodimers of an 18kDa
a-subunit disulphide linked to one of two 13kDa b-subunits (bA
and bB) resulting in inhibin A (abA) and B (abB) respectively.
Primarily of gonadal origin, inhibins regulate pituitary follicle-
stimulating hormone secretion by feedback inhibition. In humans,
women produce both inhibin A and inhibin B (Welt et al, 1999;
Welt and Schneyer, 2001), whereas in adult men inhibin B is the
primary form (Marchetti et al, 2003). Inhibins have also been
shown to be expressed in adrenal cortex, pituitary and prostate
(reviewed in Risbridger et al, 2001). Other endocrine and paracrine
functions of inhibins involve regulating members of the TGFb
superfamily, such as TGFb itself, activins and bone morphogenic
protein (BMP), by competing for their receptors (Wiater and Vale,
2003; Farnworth et al, 2007). This antagonistic effect of inhibin is
amplified in the presence of the inhibin receptor, TGFb receptor
III (TGFbRIII), also known as betaglycan.
The first study that linked inhibin to reproductive cancers
showed that serum inhibin increased in women with granulosa cell
tumours of the ovary (Lappohn et al, 1989) and inhibin currently
serves as a robust biomarker for this cancer. A direct biological
function for inhibin in carcinogenesis was demonstrated by
Matzuk et al (1992) when they created the inhibin-a subunit
(INHa) knockout mouse. Both sexes developed gonadal sex-cord
stromal tumours with high penetrance and developed tumours
in their adrenal glands after castration, showing that INHa can act
as a tumour suppressor. Subsequent mouse model studies revealed
a complex network of interactions involving inhibin, activin and
other modifiers in the development and progression of gonadal
and adrenal tumours in INHa-deficient mice (reviewed in
Risbridger et al, 2001). Although it is clear that total inhibin as a
serum test has utility in the initial detection and prognosis
of certain types of ovarian cancers, the biological function of
inhibin in tumourigenesis is far from clear.
We have observed both up- and down-regulation of INHa
expression in prostate cancer (PCa) tissues dependent on the stage
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sof disease. Studies from our laboratory on metastatic PCa epithelial
cell lines demonstrated that high concentrations (400ngml
 1)o f
recombinant inhibin A inhibited growth of androgen-responsive
LNCaP cells, but not androgen-independent DU145 cells, suggest-
ing that the effect of inhibin may be dependent on cell phenotypes
related to specific stages of PCa (McPherson et al, 1997). Further-
more, we have shown loss of heterozygosity or epigenetically
regulated loss or down-regulation of INHa in PCa patient samples
and LNCaP, DU145 and PC3 cell lines (Mellor et al, 1998; Schmitt
et al, 2002; Balanathan et al, 2004). Collectively, these data suggest
a tumour suppressive function for INHa in the prostate. In
contrast, new insights into the role of INHa in the prostate came
from a recent study using a large cohort of PCa patient tissues that
showed that INHa was frequently over-expressed in high-grade
PCa (Risbridger et al, 2004a,b). The intensity of INHa immuno-
reactivity was associated with a higher risk of recurrence of PCa.
These variable clinical and experimental observations provide
equivocal evidence for a role of INHa in PCa. Thus it was proposed
that like TGFb (Roberts and Wakefield, 2003), INHa has tumour
suppressive activity in normal epithelial cells, which changes to
tumour promoting in cancer cells (Ball et al, 2004; Risbridger et al,
2004a).
To date there is no proof that INHa can increase tumourigenesis
and metastasis. Thus the primary aim of this study was to examine
the pro-tumourigenic and pro-metastatic function of INHa in
advanced PCa. Specifically, the expression profile of INHa and
clinicopathological parameters were examined in primary PCa
tissues including specimens from patients with organ-confined
disease and those with metastasis to the lymph nodes. In addition,
human metastatic PCa cell lines, LNCaP and PC3, were used in
in vitro and in vivo functional studies to determine the biological
function of elevated levels of INHa on migration, invasion, tumour
growth and metastasis.
MATERIALS AND METHODS
Analysis of clinical material
Relationship between INHa expression and clinicopathological
parameters in primary prostate adenocarcinomas This study was
conducted in accordance with Australian National Health and
Medical Research Council (NHMRC) guidelines. Archival forma-
lin-fixed paraffin-embedded tissue blocks were retrieved from
37 patients with prostate carcinoma who underwent radical
prostatectomy. The clinicopathological characteristics, vascular
endothelial growth factor-C (VEGF-C) expression, lymphatic
vessel density (LVD) and lymph node status of this cohort have
been described previously (Zeng et al, 2004, 2005). We conducted
a cross-sectional study to determine whether INHa expression
was associated with clinicopathological parameters (Gleason
score, surgical margins, extracapsular spread, VEGF receptor-3
(VEGFR-3) expression and lymph nodes status) and/or linked to
well-established prognostic factors in prostatic adenocarcinoma.
The PO 12 antibody (kindly provided by Dr Nigel Groome) was
used to determine the expression pattern of INHa in primary
prostate tissues as previously described (Risbridger et al, 2004b).
Each immunostained tissue section was assessed and staining
intensity in benign epithelial, cancer (Gleason grade G3/G4) and
stromal regions was scored from 0 to 4 with 0 representing
negative staining and 4 representing very strong positive staining.
The relative risk of PCa patients being positive for the respective
parameters was determined.
Stable transfection of LNCaP and PC3 cell lines LNCaP and PC3
were obtained from American Type Culture Collection (Rockville,
MD, USA) and routinely cultured as described previously
(Balanathan et al, 2004). Expression vectors pcDNA3.1 (empty
vector, EV) and human INHa cDNA subcloned into pcDNA3.1
(pcDNA3.1 (INHa)) were purchased from Invitrogen (Mount
Waverley, Victoria, Australia) and prepared for transfection
according to the manufacturer’s instructions. LNCaP and PC3
cells were transfected using Lipofectamine plus (Invitrogen) and
Superfect (Qiagen, Doncaster, Victoria, Australia) respectively
according to the manufacturer’s instructions. Individual colonies
surviving after 2–3 weeks selection were picked and propagated
for analysis.
Confirmation of mRNA expression in INHa-transfected LNCaP and
PC3 cell lines Total RNA was extracted using RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions. Reverse
transcription (RT) was performed as previously described
(Balanathan et al, 2004). b2-microglobulin (b2mg) was used as a
housekeeping gene for block PCR. Primer sequences were: INHA,
forward: CCTGTTCTTGGATGCCTTG; reverse: AGCTGGGCTGAA
GTCACCT and b2mg, forward: CCGTGTGAACCATGTGACTT;
reverse: CAAACATGGAGACAGCACTC. Absolute quantitative
real-time analysis was used to assess the levels of TGFbRIII mRNA
expression in the clones. The analysis was performed on a
LightCycler real-time PCR machine (Roche Diagnostic, Mannheim,
Germany) using LightCycler Fast Start DNA Master SYBR Green 1
(Roche Diagnostic) according to the manufacturer’s instructions.
All experiments were carried out twice and duplicate readings were
taken for each replicate. The quantity of mRNA was determined
using a standard curve and all values were normalised using the
housekeeping gene, hypoxanthine ribosyl transferase (HPRT).
Primer sequences were: TGFbRIII, forward: TTCCCTGTTCACCC
GACCTGAAAT; reverse: CGTCAGGAGGCACACATTA and HPRT,
forward: TGTAATGACCAGTCAACAGGG; reverse: TGGCTTATAT
CCAACACTTCG.
Confirmation of protein expression by ELISA Cell lysates and
conditioned media (conditioned for 24h) were prepared from
EV- and INHa-transfected clones. Total protein (1mgml
 1) was
used for further analysis. Inhibin A and B and activin A concen-
trations were measured in triplicate using specific ELISA according
to the manufacturer’s instructions (Diagnostic Systems
Laboratories, Webster, TX, USA). VEGF-A and VEGF-C ELISAs
were measured in duplicate using specific ELISA according to the
manufacturer’s instructions (R&D Systems, Minneapolis, MN,
USA). Two biological replicates were examined.
Direct cell counting: proliferation assay LNCaP and PC3 cells
were seeded at a density of 1 10
5 cells per well and 5 10
3 cells
per well, respectively, in 24-well plates and incubated at 371C.
Triplicate wells were harvested by trypsinisation on days 1, 2, 3, 4
and 5, and numbers of cells per well were counted using haemo-
cytometer. Each experiment was repeated twice. The results
obtained from individual clones (EV and INHa) were pooled for
each treatment.
Scratch wound assay: motility assay Cells were plated in triplicate
in 6- or 12-well plates and grown until approximately 70–80%
confluence. The cell monolayer was then wounded and analysed
over time as previously described (Sharp et al, 2004). Each
experiment was repeated twice. The results obtained from
individual clones (EV and INHa) were pooled for each treatment.
Intra-prostatic inoculation of LNCaP and PC3 cells The experi-
ments were in accordance with NHMRC of Australia guidelines.
LNCaP (2 10
6) or PC3 (5 10
5) clones were injected orthotopi-
cally into the ventral lobe of the prostate gland (10 animals per
clone) of male SCID mice as previously described (Zeng et al,
2006). After 7–9 weeks, mice were killed and primary prostate
tumours were removed and weighed. In addition, regional lymph
nodes were removed for analysis. Monoclonal human mitochon-
dria antibody (1:100; Chemicon, Temecula, CA, USA) was used to
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previously described (McCulloch et al, 2005). The monoclonal
R1 antibody (7.5mgml
 1), kindly provided by Dr Nigel Groome,
was used to determine INHa expression in tumours as previously
described (Balanathan et al, 2004).
Lymph node volumes were determined using stereological
analysis as previously described (McPherson et al, 2001). The
lymph nodes were serially sectioned at 5mm thickness and using
a random sampling scheme, every 20th section was chosen for
analysis. Briefly, the computer program newCAST component
(version 2.14; Visiopharm, Hørsholm, Denmark) was used to
generate a point grid, and volumes of the lymph nodes were
determined. Each section was examined using  20 magnification
and tissue sections were mapped to define tissue boundaries and
were sampled at predetermined intervals along x- and y-axes using
a single grid-counting frame. The volume was then determined
using the equation¼no of points for each tissue area per
point distance; in this case the distance was defined by thickness
of the sections (5mm) plus (5mm 20 for every 20th section).
LVD in the intra-prostatic tumours Lymphatic vessels were
identified using lymphatic vascular endothelial hyaluronan recep-
tor (LYVE-1), a marker of lymphatic endothelium (Banerji et al,
1999). Invasion of tumour cells into lymphatics was monitored
by the presence of human mitochondrial protein-stained cancer
cells in lymph vessels. Double immunostaining for LYVE-1 and
mitochondria was performed on a Dako Autostainer (Dako,
Glostrup, Denmark). The sections were incubated with LYVE-1
antibody (Fitzgerald, Boston, MA, USA) diluted at 0.5mgml
 1 for
2h. LYVE-1 was detected by incubation with Envision polymer-
anti-rabbit-HRP (Dako) for 15min and visualised with diamino-
benzidine (Dako). Sections were then incubated with Double
Staining Enhancer (Zymed, San Francisco, CA, USA) for 15min
and exposed to mitochondrial antibody (Chemicon) diluted at
1:200 for 2h. Secondary antibody, biotinylated rabbit anti-mouse
IgG1 (Zymed) was applied and the immunoreactivity was detected
by ExtrAvidin-Alkaline phosphatase (Sigma, St Louis, MO, USA)
and visualised by reaction with Vector Red (Vector Laboratories,
Burlingame, CA, USA). The sections were counterstained with
hematoxylin (Dako) and immunolocalisation was examined using
an Olympus BX-60 microscope (Tokyo, Japan).
Lymphatic vessels were counted using stereological methods as
previously described (Balanathan et al, 2004). Lymphatic vessels
were counted within tissue sections (of randomly selected INHA-
positive prostate tumours, n¼15 and EV tumours, n¼11; using
n¼2 randomly selected sections per tumour) to assess the LVD
within the tumour (intra-tumoural) region, the region in contact
with both the tumour and the stroma (peritumoural) and the
region away from tumour. LVD was expressed as the number of
lymph vessels per mm
2.
Statistical analyses All statistical analyses were performed and
results were analysed by ANOVA or t-tests as specified. The
relationships between INHa expression and clinicopathological
parameters were evaluated by Fisher’s exact test. The mean
staining intensity of patients positive for each of the respective
clinicopathological parameter was compared to the mean staining
intensity (reference) of those patients who were negative. The
relative risks and 95% confidence intervals (CI) were estimated.
RESULTS
Relationship between INHa expression and
clinicopathological parameters in primary prostate
adenocarcinomas
Immunostaining revealed differential expression of INHa in
benign epithelial, G3/G4 cancer regions as well as in the stroma
of primary PCa tissues from patients with organ-confined disease
(Figure 1A–D) and those with metastasis to the lymph nodes
(Figure 1E–H). Association between clinicopathological prog-
nostic factors and INHa expression is shown in Table 1. Elevated
expression of INHa in the benign epithelial regions of the primary
PCa tissues showed a higher relative risk in PCa patients positive
for extracapsular spread (P¼0.01). Similarly, elevated expression
of INHa in the stroma of the primary PCa tissues showed a higher
risk of PCa patients positive for extracapsular spread (P¼0.0011),
surgical margins (P¼0.0006), VEGFR-3 expression (P¼0.00067)
and lymph node metastasis (Po0.0001). Further analysis showed
that there was a significant increase in INHa staining in benign
epithelial (P¼0.018) and stromal (Po0.0001) regions but not in
G3/G4 cancer regions in tissues from patients with lymph node
metastasis compared to patients with organ-confined disease (data
not shown).
Isolation and characterisation of cells over-expressing
INHa
The INHa expression profile in clinical specimens suggests pro-
tumourigenic and pro-metastatic function for INHa in advanced
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Figure 1 INHa expression in clinical specimens and its association to prostate disease. Immunohistochemical staining of INHa in primary prostate
tumours from PCa patients with (A–D) organ-confined (negative) and (E–H) metastatic disease (positive). INHa immunostaining intensity in benign
epithelial, cancer region (G3/G4) and stromal regions (S) is shown. Inset shows IgG control. Bar¼200mm. B, D, F and H are enlargements of A, C, E and
G, respectively.
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expression on PCa cells, we stably transfected LNCaP and PC3 cell
lines with an expression vector containing an INHa cDNA or with
a control EV and confirmed the expression of the transgene by
PCR (Supplementary Figure 1). Expression of dimeric proteins
(inhibin A, inhibin B and activin A) was examined by ELISA.
Analysis of cell lysates and conditioned media identified an
increase in expression of inhibin B, but not inhibin A in INHa-
transfected LNCaP cells and both inhibin A and inhibin B in the
INHa-transfected PC3 cell lines (Table 2). There was no change in
activin A level in the transfected cells. The expression of INHa
protein was also validated by western blot and immunohisto-
chemistry (data not shown). Immunohistochemistry of antibiotic
selected clones revealed that the selected INHa-transfected clones
were a heterogeneous population of INHa-positive and -negative
cells. Because primary PCa cells are known for their heterogeneity
and the aim of this study was to determine the effect of elevated
levels of INHa in cancer, it was concluded the heterogeneous
population was not going to bias the outcomes of the functional
assays.
Growth characteristics of INHa-transfected LNCaP and
PC3 clones in vitro
To evaluate the effect of over-expression of INHa on the growth
of LNCaP and PC3 cell lines, we examined the proliferative
capacity and motility of the various clones. Direct cell count
demonstrated reduced proliferation of INHa over-expressing
LNCaP cells (Figure 2A) and increased proliferation of PC3 cells
(Figure 2B) when compared to their respective EV clones in the
later stages of the growth curve. Monolayer wound healing assays
showed INHa over-expressing LNCaP cells had a reduced rate of
wound closure at earlier time points (Figure 2C) whereas INHa
over-expressing PC3 cells demonstrated a trend towards increased
rate of wound closure (Figure 2D). Because the significant changes
in proliferation and motility observed in this study occur at
different time points, it suggests that they are independent from
each other.
Effect of INHa over-expression on tumour growth and
metastasis
The influence of INHa on tumour growth and metastasis was
determined in vivo. The clones were injected at the orthotopic site
(prostate) and after 7–9 weeks primary prostate tumours as well as
the adjacent lymph nodes were harvested. Primary prostate
tumour size was determined and the incidence of lymph node
metastasis was scored. Positive immunostaining for human
mitochondrial protein confirmed that the primary and secondary
tumours originated from intra-prostatic injection of human cells.
INHa immunostaining was used to confirm INHa expression in
tumours (Figure 3A–D, left). Immunostaining in the INHa
tumours showed that INHa expression was not uniform within
the tumour, which is consistent with a heterogeneous population
of INHa-positive and -negative cells in the INHa-transfected clones
Table 1 Relationships between the expression of INHa and clinicopathological parameters in prostate adenocarcinoma (n¼37)
Benign regions Cancer regions (G3/G4) Stromal regions
Parameters
No. of
specimens
Mean
intensity
Relative risk
(95% CI) P-value
Mean
intensity
Relative risk
(95% CI) P-value
Mean
intensity
Relative risk
(95% CI) P-value
Combined Gleason grade
6 16 0.7 NA 1.88 NA 0.30 NA
7 14 1.51 NA 2.21 NA 1.21 NA
X8 7 1.29 NA 1.99 NA 2.00 NA
Extracapsular spread
Positive 24 1.43 2.13 1.41
Negative 13 0.65 (reference) 2.07 (1.04–4.13) 0.01
a 1.87 (reference) 1.27 (0.76–2.11) NS
a 0.08 (reference) 2.55 (1.39–4.65) 0.0011
a
Surgical margins
Positive 16 1.15 1.84 1.47
Negative 21 1.12 (reference) 1.15 (0.68–3.08) NS
a 2.18 (reference) 0.71 (0.32–1.53) NS
a 0.50 (reference) 4.75 (1.62–13.93) 0.0006
a
VEGFR-3+ vessels
Positive 18 1.29 2.07 1.53
Negative 19 0.97 (reference) 1.27 (0.62–2.60) NS
a 2.00 (reference) 1.20 (0.0–2.39) NS
a 0.33 (reference) 2.85 (1.28–6.37) 0.0067
a
Lymph node metastasis
Positive 16 1.41 2.06 1.93
Negative 21 1.01 (reference) 1.62 (0.67–3.97) NS
a 2.00 (reference) 0.84 (0.48–1.46) NS
a 0.15 (reference) 13.22 (1.94–90.00) o0.0001
a
Abbreviations: VEGFR¼vascular endothelial growth factor receptor; NA¼not applicable; NS¼not significant; CI¼confidence interval.
aFisher’s exact test.
Table 2 Inhibin A, inhibin B and activin A protein expression in INHa
clones
Cell lysates Conditioned media
Cell Inhibin A Inhibin B Activin A Inhibin A Inhibin B Activin A
lines (pgml
 1) (pgml
 1) (ngml
 1) (pgml
 1) (pgml
 1) (ngml
 1)
LNCaP
L16
a o10 166.3 o0.011 o10 o10 o0.011
L17
a o10 137.4 o0.011 o10 o10 o0.011
L18
a o10 118.5 o0.011 o10 o10 o0.011
L1
b o10 433.6 o0.011 o10 88 o0.011
L5
b o10 183.8 o0.011 o10 24.7 o0.011
L8
b o10 308.7 o0.011 o10 161.8 o0.011
PC3
P128
a 50.1 67.2 1.960 76 o10 8.860
P129
a 56 64.1 1.780 80.8 o10 7.520
P130
a 48.1 73 1.720 74.6 o10 8.820
P20
b 228.1 149.7 1.280 197 185 7.320
P103
b 194.1 186 1.690 132.3 226.4 9.340
P104
b 221.6 187.8 1.670 194.9 177.3 11.320
aEV-transfected clones.
bINHa over-expressing clones.
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swe had observed previously. INHa immunostaining of the lymph
nodes showed INHa-positive LNCaP cells to be distributed
throughout the lymph node tumours whereas INHa-positive PC3
cells were confined to the outer tumour regions (Figure 3C and D,
left). INHa over-expression in LNCaP cells did not affect
orthotopic tumour take but significantly reduced the size of the
primary tumour (P¼0.0029) compared to the EV-transfected
clones (Figure 3A, middle and right). Furthermore, INHa over-
expression in LNCaP cells did not change the incidence of lymph
node metastasis or the size of the lymph node tumours (Figure 3C,
middle and right). INHa over-expression in PC3 cells had no effect
on orthotopic tumour take but a significant increase in the
primary prostate tumour size (P¼0.005) was observed (Figure 3B,
middle and right). INHa over-expression in PC3 significantly
increased the incidence of lymph node tumours (P¼0.0341) and
lymph node tumour size (P¼0.0047) compared to the EV-
transfected clones (Figure 3D, middle and right). The altered
tumour size following INHa over-expression may have influenced
the formation of metastasis.
LVD and invasion of tumour cells into lymphatics in INHa
over-expressing primary prostate tumours
Changes to LVD and lymphangiogenesis are often associated with
metastatic spread of cancer cells to the lymph nodes (Mattila et al,
2002; Zeng et al, 2005). To understand the mechanisms and to
provide proof of metastatic spread observed in the mice injected
with INHa-positive cells, we stained LNCaP and PC3 INHa and EV
orthotopic tumours for LYVE-1, and human mitochondrial
antibody to determine LVD and the degree of invasion of tumour
cells into lymphatic vessels (lymphatic invasion) in the tissues.
Consistent with our previous study (Zeng et al, 2006), the analysis
of LNCaP tumours in the present study was complicated by the
significantly larger size of the tumours compared to PC3 tumours.
This larger size resulted in numerous necrotic areas in the LNCaP
tumours, making it difficult to consistently define the different
tumour peripheries and the intra- and inter-tumoural regions. For
this reason stereological analysis of the LNCaP tumours was not
possible. However, histological evaluation of the LNCaP tumours
demonstrated no LYVE-1-positive lymphatic vessels within the
tumour with lymphatic vessels only present in the regions away
from the tumour (Figure 4A and B). In contrast, PC3 tumours had
lymphatic vessels distributed throughout the tumour (Figure 4C
and D). Stereological analysis of the PC3 tumours revealed a
significant increase (P¼0.0023) in total LVD in the intra-tumoural
regions with no difference in LVD in peritumoural regions and
regions away from tumour in INHa-positive tumours compared
to the controls (Figure 4E). A significant increase in lymphatic
invasion in the intra-tumoural (P¼0.0002), peritumoural
(P¼0.0225) and regions away from tumour (P¼0.0077) in
INHa-positive tumour tissues compared to the controls was
evident (Figure 4F).
Factors inducing tumour growth and metastasis in INHa
over-expressing PC3 tumours
The observed increase in LVD in INHa-positive PC3 tumours
suggests that the metastatic spread of the cancer cells from the
primary tumour site to the lymph nodes occurs through the
process of lymphangiogenesis. Because VEGF-A and VEGF-C have
been implicated in inducing/promoting metastasis to the lymph
nodes in PCa (Karkkainen et al, 2002; Weis and Cheresh, 2005;
Zeng et al, 2006), we went on to determine the expression of
VEGF-A and VEGF-C proteins by ELISA (Table 3) in INHa- and
EV-transfected clones in vitro. There was no significant change in
the amount of VEGF-A and VEGF-C secreted by the different
LNCaP clones. VEGF-C protein was significantly increased
(P¼0.0011) in the INHa over-expressing PC3 clones compared
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Figure 2 Effect of INHa over-expression on proliferation and motility of LNCaP and PC3 cells, in vitro.( A and B) Direct cell counts for EV- and INHa -
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mean.
Role of INHa in advanced PCa
P Balanathan et al
1788
British Journal of Cancer (2009) 100(11), 1784–1793 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sto their EV clones, however there was no significant change in
secreted VEGF-A levels.
Expression of TGFbRIII in LNCaP and PC3 transfected
clones
Although being a receptor for TGFb, TGFbRIII is also a receptor
for inhibins (Wiater and Vale, 2003), and recent studies have
reported loss of TGFbRIII as a common and important event in
human PCa (Turley et al, 2007; Sharifi et al, 2007a). Down-
regulation of TGFbRIII in PCa has been suggested to reflect loss of
sensitivity to tumour suppressive inhibin by the PCa cells. To test
this hypothesis, we determined the levels of TGFbRIII mRNA
expression in the clones. Consistent with a recent study (Sharifi
et al, 2007a), real-time analysis of PCa cell lines revealed LNCaP
cells to have more TGFbRIII mRNA expression compared to PC3
cells. There was no change in TGFbRIII expression in INHa-
transfected LNCaP or PC3 clones compared to EV-transfected
clones (Figure 5).
DISCUSSION
Although inhibin is used as a biomarker for ovarian cancer, the
biological function of elevated levels of INHa expression in PCa
and certain types of ovarian cancer is unclear. This study is the
first functional study to link up-regulation of INHa expression
in androgen-independent prostate disease and progression of
primary prostate and secondary tumours and metastasis.
We conducted a cross-sectional study to determine a link
between INHa expression and a number of clinicopathological
parameters: Gleason score, surgical margin status, extracapsular
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Figure 3 Effect of INHa over-expression on primary prostate tumour growth and lymph node metastasis. (A–D) Left, immunohistochemistry of primary
prostate and lymph node tumours using human mitochondria and INHa staining confirmed the human origin of the cells in LNCaP- and PC3-inoculated mice
and INHa expression in the tumours. Bar¼200 and 500mm. (A and B) Primary prostate tumour weights (middle) and primary prostate tumour take (right).
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sspread, lymph node status and VEGFR-3 expression, which are
well-established prognostic factors of PCa (Wheeler et al, 1998;
Cheng et al, 1999, 2001, 2005; Li et al, 2004). This study showed
that an elevated level of INHa expression in the primary prostate
tumour can be used as a predictive factor for prognosis in PCa.
Univariate analysis showed a significant association between
elevated levels of INHa in primary PCa tissues and extracapsular
spread, surgical margins, VEGFR-3 expression and lymph node
status. This finding is supported by our previous study that
reported elevated levels of INHa in PCa patients to be associated
with a higher risk of recurrence, although this association was not
statistically significant (Risbridger et al, 2004b). The proposed
cellular site for INHa expression and action is epithelial cells,
however our immunostaining and analysis of the primary prostate
tumour showed a significant association of elevated levels of INHa
in both benign epithelial cells and stromal cells to extracapsular
spread. There is increasing evidence that the surrounding
microenvironment also has a major function in cancer cell growth,
survival, invasion and metastatic progression, further supporting
the pro-tumourigenic and pro-metastatic function of INHa in
advanced PCa (reviewed in Chung et al, 2005; Alberti, 2006; Taylor
and Risbridger, 2008). Likewise, Wheeler et al (1998) reported that
invasion into or through the capsule of the prostate is strongly
associated with both the ability of PCa to metastasise and with
recurrence of cancer after radical prostatectomy. Our data link
INHa expression in both epithelial and stromal cells with
extracapsular spread, which suggests a role for INHa in advanced
PCa. In addition, the observed up-regulation of INHa in benign
epithelium and stromal regions in the primary prostate tumours in
patients with lymph node metastasis suggests an association with
VEGF-C-linked metastasis. Further analysis of our clinical data
showed that INHa expression is stronger in benign epithelium and
stroma but not the G3/G4 regions of the prostate in patients with
lymph node metastasis compared to those with organ-confined
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Table 3 Effect of over-expressing INHa on VEGF-A and VEGF-C
expression
LNCaP PC3
EV
clones
INHa
clones
EV
clones
INHa
clones
VEGF-A
Secreted
protein (pgml
 1)
1751±33.48 1747±26.02 1794±40.31 1712±34.64
VEGF-C
Secreted
protein (pgml
 1)
5.86±2.66 7.82±2.13 3377±566.0 6892±531.6**
Abbreviations: EV¼empty vector; VEGF¼vascular endothelial growth factor. Data
from individual clones were pooled and presented above. **P¼0.0011.
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sdisease. In PCa, Tsurusaki et al (1999) found that VEGF-C mRNA
levels were significantly higher in lymph-node-positive tumours
and that VEGFR-3-positive vessels were increased in the stroma of
VEGF-C-positive tumours. Also, VEGF-C has been shown to
promote growth of lymphatic vessels into and around tumours in
animal models and this was associated with metastatic spread to
the lymph nodes and sometimes to distant organs (Mandriota
et al, 2001; Skobe et al, 2001; Mattila et al, 2002). Collectively, our
analysis of INHa expression in primary prostate tumour tissues
and the association to well-established prognostic factors strongly
supports a pro-tumourigenic and pro-metastatic function for
INHa in PCa.
Because the proposed cellular site for pro-tumourigenic and
pro-metastatic action of INHa is cancer epithelial cells, we over-
expressed INHA in metastatic epithelial PCa cell lines, LNCaP and
PC3, to evaluate functionally the effect of elevated levels of INHa in
PCa. A key event in the progression of PCa is the transition from
an androgen-dependent to -independent stage, where subpopula-
tions of tumour cells either gain resistance to, or adapt to, an
androgen-depleted environment, and begin to proliferate resulting
in the progression to highly aggressive and metastatic androgen-
independent disease. Furthermore, when PCa is advanced or
metastatic it is usually incurable and tends to metastasise to bone
and lymph nodes. LNCaP cells, originally isolated from a lymph
node metastasis (Horoszewicz et al, 1980, 1983), have retained
their ability to respond to androgens, whereas PC3 cells, originally
derived from a bone metastasis (Kaighn et al, 1979), are androgen
independent. Thus these cell lines represent early and late stages of
metastatic prostate disease.
INHa over-expression in LNCaP cells demonstrated reduced
cell proliferation, migration and primary prostate tumour growth
whereas INHa over-expression in these cells did not change the
cells’ ability to metastasise to the lymph nodes nor did it influence
the growth of the lymph node tumours. The lack of change
in VEGF-C expression in INHa-transfected LNCaP cells is
consistent with the unchanged metastatic ability of LNCaP cells
in vivo. In contrast, INHa over-expression PC3 cells demonstrated
increased cell proliferation, migration, primary prostate tumour
and lymph node tumour growth. These cells showed increased
metastasis to the lymph node, which was accompanied by an
elevation of LVD and tumour cell invasion into lymphatics. These
effects were associated with up-regulation of VEGF-C. Similarly,
Karpanen et al (2001) reported that VEGF-C expression in a
mouse tumour model strongly promoted the growth of tumour-
associated lymphatic vessels, which in the tumour periphery were
commonly infiltrated with the tumour cells. Although limited to
the use of only two cell lines, the current study is the first to
functionally show a pro-tumourigenic and pro-metastatic function
for INHa in an androgen-independent model of metastatic
prostate disease.
Another explanation for the different effects of INHa observed
in the current study is the loss or gain of a yet-to-be-identified
signalling pathway for INHa in either tumour suppression or
promotion. We have shown that LNCaP cells express more
TGFbRIII mRNA expression compared to PC3 cells and that the
level of TGFbRIII mRNA expression is maintained after INHa
over-expression. Loss of TGFbRIII during PCa progression has
been suggested to be a reason for loss of sensitivity to the tumour
suppressive effect of inhibin in prostate disease (Turley et al, 2007;
Sharifi et al, 2007a,b). Whether androgen status, different cell
types and/or levels of TGFbRIII expression are responsible for the
different effects of inhibin observed in the present study is an
important area of future investigation.
Inhibins are known to be involved with regulating members
of the TGFb superfamily, including TGFb itself, as well as
activins and BMP, by competing for their receptors or co-receptors
(Wiater and Vale, 2003; Farnworth et al, 2006, 2007). However,
unlike other members of the TGFb superfamily (Pangas and
Woodruff, 2000; Shi and Massague ´, 2003), the signalling path-
way(s) for inhibin have not yet been defined. Although it remains
unclear how INHa mediates downstream cellular events leading to
prostate disease, the observed effect of INHa in the present study
suggests and supports an effect of inhibin which is independent of
TGFb/activin in PCa. Owing to the presence of both bA and bB
subunits in LNCaP and PC3 cells, the clones were able to produce
dimeric inhibin A and inhibin B. The presence of inhibin B in both
LNCaP and PC3 cells is significant as inhibin B is the pre-dominant
form of inhibin in men and therefore more relevant to the study of
PCa. Although the presence of inhibin A in PC3 may be of
relevance to the observed phenotypes of PC3 cells, further
investigation into the functional difference resulting from inhibin
A vs inhibin B production in these cells was beyond the scope of
this project. The level of inhibin A and inhibin B produced by the
cells reflects the level of the b-subunits expressed and secreted by
the respective cell lines (McPherson et al, 1999). Our study showed
no change in the levels of activin A (bAbA), which indicates that
observed effects are specific to inhibin and not a response to
activin levels. Therefore, although TGFb/activins have been shown
to induce expression of angiogenic/lymphangiogenic factors
through P13K and/or SMAD2 pathways (Wagner et al, 2004;
Kang, 2006) and TGFb/activins inhibit growth of PCa cells
(Wilding et al, 1989; Wang et al, 1996; McPherson et al, 1997),
the different responses of the PCa cell lines to elevated levels of
INHa we have observed cannot be simply explained by abrogation
of TGFb/activin signalling. Thus, the effect of inhibin on LNCaP
cells observed in this study supports a role for inhibin in PCa
independent of TGFb/activin. Also, the increased metastatic ability
of INHa observed in INHa over-expressing PC3 cells cannot be due
to antagonism of activin action because of the simultaneous
expression of follistatin in these cells (McPherson et al, 1999).
Follistatin is an activin-binding protein that binds to activin with a
high affinity thereby inhibiting activin bioactivity (Phillips and de
Kretser, 1998). Taken together, the current study demonstrates a
direct action of INHa in PCa that is context and/or cell-type
dependent.
In summary, this study showed both benign epithelial and
stromal regions of primary prostate tumours to be the sites of
INHa expression. We have also demonstrated a strong association
of elevated levels of INHa to well-established prognostic factors of
PCa. This finding has identified INHa as a very important predic-
tive factor that can be used to identify patients at increased risk for
disease progression and cancer death after radical prostatectomy,
so that appropriate therapy can be selected. Finally, the current
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Figure 5 TGFbRIII expression in LNCaP and PC3 clones. Total RNA
(2.5mg) was reverse transcribed (RT) and absolute quantitative real-time
analysis was performed to determine the levels of TGFbRIII mRNA
expression in the EV- and INHa-transfected clones. The bars represent EV-
transfected LNCaP and PC3 clones in grey, INHa-transfected LNCaP and
PC3 clones in black. Data are shown as mean±s.e. of the mean.
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sstudy has shown a pro-tumourigenic and pro-metastatic role for
INHa in an androgen-independent model of metastatic prostate
disease. This suggests that in the absence of androgens, elevated
levels of inhibin may be driving the more aggressive and metastatic
phenotypes of PCa tumour.
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